# Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation

> **NCT01516567** · PHASE2 · COMPLETED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 47 (actual)

## Conditions studied

- Primary Mediastinal Large B Cell Lymphoma

## Interventions

- **DRUG:** Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab

## Key facts

- **NCT ID:** NCT01516567
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04-01
- **Primary completion:** 2017-04
- **Final completion:** 2022-11-16
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-02-09

## Collaborators

- Children's Oncology Group

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01516567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01516567, "Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01516567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*